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Currently, the therapy for breast cancer is determined by immunohistochemical staining of the primary tumour for oestrogen
receptor alpha (ERa). However, a proportion of ERa-positive patients fail to respond to tamoxifen and a proportion of ERa-negative
patients show response. Here, we describe a novel procedure for the purification of malignant breast epithelial cells in an attempt to
identify these patients at an early stage. Using this procedure, we are able to purify malignant cells to 490% purity as determined by
immunohistochemical staining, cytology and fluorescent in situ hybridisation (FISH). While the malignant cells can be maintained in
culture they do not proliferate in contrast to purified breast epithelial cells from reduction mammoplasties. Moreover, ERa and
progesterone receptor (PR) expression is maintained in malignant cells, whereas normal epithelial cells rapidly lose ERa and PR.
Functional studies were performed on the separated malignant cells in terms of their response to oestradiol and tamoxifen. Four out
of the seven ERa-positive tumours showed a significant reduction in cell numbers after tamoxifen treatment compared to oestradiol,
ERa negative tumours failed to show a response. We conclude that (a) it is possible to purify and maintain breast cancer cells for a
sufficient period to permit functional studies and (b) ERa is retained in culture facilitating the use of these cells in studies of the
mechanism of endocrine response and resistance in vitro.
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The human mammary gland is comprised of two epithelial cell
components, namely luminal epithelial and myoepithelial cells,
both of which can be purified by immunoaffinity techniques that
exploit differences in cell surface protein expression (Clarke et al,
1994; Gomm et al, 1995, 1997a; Kamalati et al, 1999; Niranjan et al,
1995; Page et al, 1999; Slade et al, 1999). Using such protocols, it
has been possible to further study and highlight the responses of
these two cell types to growth and morphogenic signals, thereby
gaining further insight into the functionality of these cells in
normal mammary gland function.
It is thought that luminal epithelial cells are the main precursor
cell population from which breast cancers arise, although gene
expression studies indicate that there may be myoepithelial gene
expression signature in a significant number of such tumours
(Perou et al, 1999, 2000). Nevertheless, comparison of tumour and
normal cells highlight oestrogen receptor alpha (ERa) expression
in breast cancer, a protein found to be expressed in approximately
20% of all cells in the normal mammary gland (Russo et al, 1999),
and 87% of ER-positive cells are luminal epithelial cells or in an
intermediate position in the duct wall (Petersen et al, 1987). ERa is
expressed in 50–70% of all breast cancers, where endocrine
therapy directed at inhibiting ERa function is used as a treatment
following surgery. From this, and through observations in animal
models it is clear that oestrogen is an important growth and/or
survival factor in breast cancer. However, the response of primary
human breast tumour cells to oestrogens and antioestrogens
remains poorly studied. Although there are a number of ERa-
positive breast cancer cell lines, these may not be the best vehicle
for studying in vivo response. These problems have prompted us
to evaluate the potential for immunoaffinity purification to
characterise primary human breast tumour cells. In doing this,
we sought to modify our original protocols for the purification of
normal mammary epithelial cells so that they can be applied to
both the normal and malignant mammary gland. By exploiting the
expression of epithelial cell adhesion molecule (Ep-CAM) antigen,
found on the surface of primary luminal epithelial and tumour
cells, we have been able to obtain near homogeneity in
purifications for both cell types. Surprisingly, we find that
even though both tumour and normal cells are purified using
similar protocols, ERa expression in primary normal cells is
unstable and is rapidly attenuated. By contrast, ERa expression is
stable and can be maintained in cultures of purified malignant
epithelial cells. Finally we show that, under conditions that
stimulate growth of the normal cells purified, tumour cells do
not proliferate and remain in this quiescent state, even following
treatment with oestrogen. Revised 16 December 2002; accepted 20 December 2002
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Tissues used
Fresh tissue was obtained from 82 cases of primary breast
carcinoma (Table 1) and six cases of reduction mammoplasty,
which on subsequent histopathological examination showed no
signs of malignancy or other abnormality. Of the 82 primary breast
carcinomas (Table 1), 31 were used for development of the
purification protocol/culture conditions and 19 resulted in
insufficient cells for any studies. Of the remaining 32 samples, 18
were examined cytologically and of these five were also analysed by
fluorescent in situ hybridisation (FISH) and seven were stained for
ERa/PR. Four samples were used in thymidine incorporation,
seven in the oestrogen/tamoxifen studies and the remaining three
were used for adherence studies. All patients were treated at
Charing Cross and West Middlesex Hospitals, London, and gave
written, informed consent as required by the local Ethics Review
Board.
Purification of normal human mammary luminal
epithelial cells
Cells were purified from breast tissue from reduction mammo-
plasties using a modification of procedures described previously
(Gomm et al, 1995; Slade et al, 1999). Briefly, breast tissue was
minced and digested overnight at 371C with type IA collagenase
(1mgml
 1) in RPMI-1640 plus 5% foetal calf serum (FCS) and
2m ML -glutamine, 100Uml
 1 penicillin, 0.1mgml
 1 streptomycin,
50Uml
 1 polymixin B, 2.5mgml
 1 amphotericin B. Following
digestion, the fat was decanted off and the remaining organoids
and cells were washed three times in media. Organoids were left to
settle out for 20min, the supernatants were removed, and
resuspended in RPMI-1640 containing 1% FCS. After two further
rounds of sedimentation, they were digested with trypsin/EDTA
(0.05/0.02% in PBS) plus 0.4mgml
 1 DNaseI for 15–30min at
371C and the reaction was terminated by the addition of cold RPMI
plus 10% FCS. Epithelial cells were immunoaffinity purified using
superparamagnetic, polystyrene beads (Dynal Ltd, New Ferry,
Wirral, UK) coated with a mouse IgG1 monoclonal antibody (MAb
Ber-EP4) specific for two (34 and 39kDa) glycopolypeptide
membrane antigens (Latza et al, 1990). Purified cells were
subsequently cultured in BCM (DMEM:F-12 (1:1), supplemented
with 15mM Hepes, 2mML -glutamine, 100Uml
 1 penicillin,
0.1mgml
 1 streptomycin, 50Uml
 1 polymixin B, 2.5mgml
 1
amphotericin B, 5mgml
 1 insulin, 10mgml
 1 apo-transferrin,
100mM ethanolamine, 1mgml
 1 hydrocortisone and 10ngml
 1
EGF) containing 10% FCS (Gomm et al, 1995, 1997b; Slade et al,
1999).
Purification of malignant epithelial cells from primary
tumours
The tissue was minced and digested as above. However, the
digestion was continued only until predominantly a single-cell
suspension was achieved (usually 2–5h). Undigested material was
removed using a 50mm pore nylon mesh. Tissue remaining on the
mesh was subjected to further collagenase digestion (1–3h) and
again filtered through a 50mm pore nylon mesh. The two filtrates
were refiltered with progressively smaller filter sizes (50–28mm).
Under these digestion conditions, the majority of normal epithelial
cells remained in intact organoids or as clumps and were removed
by the filtration steps. The tumour cells were purified as described
above and isolated cells were cultured in BCM with 5% FCS (FCS
concentrations from 1 to 10% were investigated and 5% resulted in
the highest cell viability after 5 days in culture (data not shown)).
Characterisation of isolated tumour cells
Purified tumour cells were cytospun and stained with hematoxylin/
eosin (H&E) and May Grunwald Giemsa (MGG). The percentage of
malignant cells was determined by conventional cytology before
purification, after purification and after 7 days in culture following
purification.
ERa and progesterone receptor (PR) expression was assessed at
different time points by immunostaining on cells fixed in Zamboni
reagent (Stefanini et al, 1967), using anti-ERa (MAb NC-ER-6F11
Novocastra, Newcastle, UK) and anti-PR (MAbPR-88, Menarini
Diagnostics, Wokingham, UK) according to manufacturers’
protocols. Cell purity was determined by staining for cytokeratins
8 and 18 (MAb CAM 5.2, Becton Dickinson, Oxford, UK).
Fluorescent in situ hybridisation (FISH) analysis of purified cells
was performed as described (Kallioniemi et al, 1992), using
centromere-specific fluorescent probes (Vysis Inc., Downers
Grove, IL, USA) for chromosomes 6, 7 and 12 (spectrum orange),
11, 17 and 18 (spectrum green) (Cajulis and Frias-Hidvegi, 1993;
Persons et al, 1996). These were used to detect aneusomy
according to the manufacturer’s instructions. Only cells exhibiting
three or more spots were deemed to be showing aneusomy.
In order to assess the viability/adherence characteristics of the
purified normal and malignant cells, 1 10
5cells were plated into
96-well plates. Three days postseeding, the medium was removed,
the adherent cells were washed twice with PBS and the washings
pooled with the medium. The number of viable and nonviable cells
were counted using trypan blue. The adherent cells were removed
by trypsinisation and counted. This process was repeated after 3
and 6 days. Purified cells from three reduction mammoplasties and
three primary tumours were assessed.
Effects of oestradiol and tamoxifen
1 10
5 cells were plated into 96-well plates. Culture medium was
changed on the third day for BCM+5% FCS containing 17b-
estradiol (E2; 10nM) or 4-hydroxytamoxifen (4 OHT; 100nM)o ra n
equal volume of the vehicle, ethanol. Total and viable (trypan blue)
cell counts were measured during the time course of the
experiment.
Table 1 Patient characteristics (n=82)
Number Percentage
Pathological size (cm)
o23 2 3 9
425 0 6 1
ER+/PR+ 57 69
ER+/PR  81 0
ER /PR+ 3 4
ER /PR  14 17
Histology
Invasive ductal 61 74
Other/mixed invasive 21 26
Nodal status
Positive 42 51
Negative 40 49
Grades
III 28 34
II 45 55
I9 1 1
This shows the total number of patients from whom tumours were obtained during
the study.
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Optimisation of purification procedure
We have previously described procedures for the purification and
culturing of normal human mammary luminal epithelial cells. In
order to adapt these techniques to the purification and culturing of
tumour cells, we have evaluated the use of Ber-Ep4 in this context.
In doing this, we have exploited the differential collagenase
treatment of normal mammary organoids compared to primary
tumour cell aggregates, which show a markedly greater sensitivity
to this process (this step is responsible for eliminating residual
normal cell within the preparation). We have been able to show
that careful use of collagenase leads to single-cell suspensions of
tumour cells with normal cells remaining in aggregates large
enough to be removed by conventional filtration. Prior to
incubation with the immunolabelled beads, the median cell
number was 1.5 10
6 (range: 1 10
5–7 10
6). After purification,
the median cell number was 3 10
5 (range: 0.3 10
5–6 10
6). We
also evaluated other parameters, including the ratio of beads to
cells required to obtain tumour cell preparations of high purity.
The number of beads: cell ratio was maximally 10:1 when there
were o10
5 cells but apart from this the optimised ratio was 3:1,
which we found to result in a high degree of purity without the
cells being completely coated with beads.
Characterisation of isolated tumour cells
Following collagenase digestion, the cells were assessed by cytology
(Table 2A) and immunostaining for cytokeratins 8 and 18
expression (Figure 1A, C). After immunobead purification, the
cells were assessed for purity and 495% of the purified cells
showed abnormal cytology, and cytokeratin staining revealed that
between 95 and 100% (mean 97%) of cells were positively stained
(Figure 1B, D). There appeared to be only 1–5% contamination
(mean¼2%), mainly because of the presence of degenerate cells
and occasional macrophages. (Table 2B displays aneusomy using
paired chromosome probes).
Immunostaining on a subset of ERa- and PR-positive tumours
over 9 days showed that these phenotypes were retained
throughout the time course studied in vitro (Table 3 and
Figure 2A–D). However, in six normal cultures studied, there
was a substantial reduction in expression of ERa and PR (Table 3
and Figure 2E–H). When this was examined in more detail, we
observed that in fact there was a substantial reduction in ERa and
PR expression within 24h and ERa expression was not observed
beyond this period whereas PR expression was lost in four cultures
by 60h (Figure 2I, J). Although this pattern of staining is not
indicative of malignancy it does indicate that the epithelial cells
isolated from the primary tumour were abnormal.
Figure 1 (A) H&E staining of cells from a primary tumour before purification, (B) H&E staining of cells from a primary tumour after purification, (C)
cytokeratin 8 and 18 staining of cells from a primary tumour before purification, (D) cytokeratin 8 and 18 staining of cells from a primary tumour after
purification (Bar represents 20mm).
Table 2A Percentage malignancy as determined by cytology before and after (day 0) immunobead selection and after 7 days in culture
% Malignancy cytology
Pre-beads Day 0 Day 7
T1 69 97 95
T2 65 97 96
T3 72 97 96
T4 88 98 95
T5 61 97 99
T6 87 100 97
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tumour maintained an abnormal genotype in culture, we carried
out FISH on a subset (n¼5) using probes for six chromosomes
and compared this with normal cells purified from reduction
mammoplasty specimens (n¼5). We compared the percentage
showing aneusomy using paired chromosome probes before and
after 7 days’ culture (Table 2B). It can be seen that between 85 and
92% of cells showed aneusomy at day 0 and 82–91% at day 7. The
figure for individual probes was 26–88%. No normal breast
epithelial cells showed aneusomy.
We examined the proportion of cells that retained viability and
adherence in a subset of samples (n¼3). Figure 3 shows that, at
day 3, more than 50% of cancer cells were viable and adhered to
plastic. At day 9, this fell to approximately 40%. In contrast, the
normal epithelial cells increased in number, so that the numbers at
day 9 were greater than the number initially seeded. There was no
evidence of proliferation of the cancer cells, despite the fact that
the MTS assay (Promega Inc., Southampton, UK) indicated
maintained cell viability (data not shown). In addition, thymi-
dine-uptake measurements showed no uptake over 16 days (data
not shown).
Effects of oestradiol and tamoxifen
We studied the effects of oestradiol (E2) and 4OHT in ERa-positive
and -negative tumours. As a result of a limited number of cells,
studies were limited to two time points. Trypan blue staining
determined viable cell numbers. The medium was changed on the
third day of culture to E2 and 4OHT-containing medium, thereby
allowing sufficient time for the cells to adhere to plastic.
Four (all ERa positive) of the seven tumours studied showed
significant reduction in cell numbers after tamoxifen treatment
compared to oestradiol treatment. The ERa-negative tumour failed
to show a response (Figure 4A). The P-values were calculated for
each tumour comparing ethanol control to oestradiol, ethanol
control to tamoxifen and oestradiol control to tamoxifen, and are
shown in Figure 4B. We have shown that oestrogen is required for
cell survival as primary tumour cells cultured in phenol red-free
media+5% double-stripped serum had a markedly reduced cell
viability within 24h (data not shown). Therefore, residual
oestrogen content of the FCS does not explain the lack of
proliferation.
DISCUSSION
We show, in this report, that enzymatic treatment of breast cancer,
followed by immunomagnetic breast cell purification, yields
extremely pure populations of breast cancer cells, as judged by
cytology and FISH. These methods have been developed as a direct
extension of our studies of normal breast cell purification (Gomm
et al, 1995, 1997a; Slade et al, 1999) and demonstrate the value of
immunomagnetic breast purification for both normal and
neoplastic breast cells. Other results presented here demonstrate
distinct differences in retention of ERa expression in normal and
cancer cells with normal cells losing ERa expression within hours
of purification. However, despite loss of ERa immunostaining in
normal cells, we have evidence of retained ERa expression since
the normal cells respond to oestrogen exposure by expressing both
PR and PS2 (Zhuang et al, 2003), both of which are known to be
oestrogen-regulated. Further, the cells show an increase in
proliferation in response to oestrogen and a decrease following
tamoxifen administration. In contrast, ERa-positive purified breast
cancer cells show a reduction in cell death following estradiol
reversed by tamoxifen, but in no case did we observe proliferation
of breast cancer cells. It is of interest that no effect of oestrogen
was seen in the ERa-negative breast cells.
Table 2B Percentage aneusomy at days 0 and 7 following purification as determined by FISH
% Aneusomy FISH
Day 0 Day 7
6 7 11 12 17 18 Total 6 7 11 12 17 18 Total
T2 25 26 75 73 43 88 92 23 – 75 72 – 81 87
T3 – 43 – 73 50 69 92 – 43 – 69 52 72 87
T4 – 44 – 63 74 70 86 62 55 71 – 72 – 91
T5 59 60 79 60 70 68 85 – – – 55 – 62 82
T6 65 68 74 – 54 – 86 58 70 78 – 46 – 85
Abnormal cytology was based on the nuclear:cytoplasmic ratio, the presence of nucleoli and the number as compared to cultured normal cells and on the increased presence of
chromatin as compared to normal cells. Cell numbers after purification: T2 2.8 10
5, T3 3.6 10
5 , T4 2.2 10
5, T5 1.2 10
5 and T6 4.5 10
5.
Table 3 ERa and PR staining of separated cells from seven primary tumours
Day 0 Day 3 Day 6 Day 9
Tumour
(ERa/PR status)
Viable
cells ERa PR
Viable
cells ERa PR
Viable
cells ERa PR
Viable
cells ERa PR
T1
(+++/+) 0.7 35.0 ND 0.4 39.6 ND 0.3 37.1 ND 0.2 32.9 ND
T4
(+++/+++) 2.0 44.0 ND 1.5 27.3 ND 1.2 21.6 ND 1.1 24.1 ND
T5
(+++/+++) 0.9 28.4 ND 0.7 25.1 ND 0.6 25.4 ND 0.5 24.4 ND
T6
(+++/+) 4.1 65.0 ND 3.1 56.8 ND 2.6 71.2 ND 2.4 67.7 ND
T7
(+++/+++) 6.0 25.3 64.4 4.5 30.9 60.4 3.0 30.7 59.2 2.7 28.8 53.6
T8
(++/++) 26.6 79.5 81.5 21.6 80.2 67.2 14.9 70.2 62.2 13.5 60.1 64.0
T9
( / ) 3.2 5.8 3 2.9 5.2 o3 2.0 5.5 o3N DN D N D
The number of viable cells is expressed as x 10
5.E R a and PR staining are expressed as a percentage. ND=not done.
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attenuated in normal cells, several mechanisms may be relevant.
Firstly, growth factor signalling is known to regulate ERa
expression through unclear mechanisms; the transcription factor
AP2U is known to be important in regulating ERa expression and
the levels of AP2U are elevated in breast cancer as compared to
normal breast (Turner et al, 1998). Recent studies (Wijayaratne
and McDonnell, 2001) have suggested a link between transcription
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Figure 2 (A)E R a staining of cells from a primary tumour after
immunobead purification (day 0), (B)E R a staining of cells from a primary
tumour (day 7), (C) PR staining of cells from a primary tumour after
immunobead purification (day 0), (D) PR staining of cells from a primary
tumour (day 7), (E)E R a staining of cells from a reduction mammoplasty
after immunobead purification (day 0), (F)E R a staining of cells from a
reduction mammoplasty (day 7), (G) PR staining of cells from a reduction
mammoplasty after immunobead purification (day 0), (H) PR staining of
cells from a reduction mammoplasty (day 7). The bar on each figure
represents 20mm, (I)E R a and PR status of primary malignant mammary
epithelial cells over 9 days expressed as the percentage change. There was
a reduction in the percentage of cells positive for both ERa and PR;
however, the majority of the malignant cells remained ERa- and PR-positive
after 9 days in culture (E)E R a (n¼6), (’)P R( n¼3), and (J)E R a and
PR status of primary normal mammary epithelial cells over 96h. Both
receptors were rapidly lost in the normal cultures, so that after 36h in
culture, all the cells were ERa and PR negative (&)E R a and (K)P R .
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Figure 3 Graph showing the viability of primary normal and malignant
mammary epithelial cells over 9 days as determined by trypan blue staining
and cell counting. The experiment started 3 days after the cells were seeded
in order to allow for cell adherence. The adherent normal epithelial cells (’)
proliferate and hence the increase in numbers after the initial reduction
between days 0 and 3. Approximately 60% of the malignant epithelial cells
were adherent after 3 days and this fell to approximately 45% 9 days after
seeding (n). The number of floating dead malignant cells (&) and the
floating live malignant cells (K) was low throughout the experiment.
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Figure 4 (A) The effects of oestradiol and tamoxifen in terms of cell
survival on malignant mammary epithelial cells (’) Oestradiol, ( )
Tamoxifen. (B) Table showing the P-values for each tumour comparing
ethanol control to oestradiol, ethanol control to tamoxifen and estradiol
control to tamoxifen. An asterisk indicates a statistically significant difference.
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equating with deceased protein stability. ERa is degraded via the
26S proteosome pathway and ubiquitination is influenced by
ligands, unliganded receptor having a short half-life. It is hence
possible that breast cancer cells, by virtue of their elevated
aromatase content, have a higher likelihood of possessing ligand-
occupied ERa (Wijayaratne and McDonnell, 2001).
Some groups have published protocols for the purification of
breast cancer cells. Most remarkable of these have been Spiers et al
(1998), who used differential centrifugation to purify different cell
types and Dairkee et al (1997), who used partial enzymatic
degradation. However, the methods used cannot exclude contam-
ination from other cell types, particularly normal epithelial cells
and fibroblasts. In Spiers’ method, overgrowth by normal
epithelial cells is suggested by the observation that ERa expression
was gradually lost over time (Speirs et al, 1998), whereas in
Dairkee’s (1997) method, contamination by fibroblasts required
differential trypsinisation. Unlike other groups (Dairkee et al,
1997), we have never observed proliferation of the purified
neoplastic cells, in contrast to the normal luminal cells, which
increased in number in the culture conditions used (Gomm et al,
1997a, b). Others have published work on transformed normal
breast epithelial cells in culture (Yaswen et al, 1990, 1992; Stampfer
and Yaswen, 1993) where resemblance to primary cancer cells may
be lost.
To overcome some of these problems, we devised an immuno-
affinity purification procedure using magnetic beads resulting in a
very pure population of epithelial cells, as judged by PCR for
luminal epithelial and myoepithelial markers. Our recent studies
have demonstrated that these two populations of cells have distinct
growth medium requirements in that epithelial cells require FCS,
EGF and FGF, whereas myoepithelial cells are growth inhibited by
FCS (Gomm et al, 1997b). We took these findings into considera-
tion when choosing media for our cells.
In conclusion, we believe that despite the limitations in cell
numbers obtained, we have established several characteristics of
these cells, including viability, cytogenetics, ERa/PR status and
response to oestrogen, and that this is a viable methodology for
purifying small numbers of primary breast cancer cells, which will
be a useful tool in the study of breast cancer biology.
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